- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02007343
Burden of Antibiotic Resistance in Gram-Negative Infections in Dutch Hospitals (GRAND-ABC)
The Attributable Burden and Costs of Infections Caused by Antibiotic-Resistant Gram-Negative Bacteria in Dutch Hospitals
Study Overview
Status
Detailed Description
This study addresses the following three aims:
- To provide a more accurate estimate than currently available of the incremental disease burden and attributable costs of antibiotic-resistant as compared to antibiotic-sensitive gram-negative bacteria (i.e. Enterobacteriaceae and non-fermenters). This analysis is focused on gram-negative infections for which patients are hospitalized. In a less detailed manner, the same analysis of disease burden and costs can be performed for acquiring a gram-negative infection during hospitalization.
- To identify determinants associated with resistance in gram-negative infections, to the extent that they are confounders of the relation between resistance and outcome.
- To adapt and optimize existing methodology to measure the burden of resistance, among others by calculating disability-adjusted life years (DALYs) which incorporate not merely mortality, but also morbidity.
GRAND-ABC is designed as a prospective parallel matched cohort, which will run for a year in each of the eight participating hospitals. The primary cohort is a random sample of all Gram-negative infections occurring in a participating hospital during the study period. This cohort can be divided on the basis of the primary determinant status (whether the Gram-negative pathogen is resistant or not based on Dutch guideline for multi-drug resistant organisms; Werkgroep Infectiepreventie (WIP). Bijzonder resistente micro-organismen (BRMO). December 2012. http://www.wip.nl/free_content/Richtlijnen/130424_BRMO.pdf) into two parallel subcohorts. Each patient in each of the subcohorts will be matched to one patient without a gram-negative infection. Together these will form the secondary cohort of non-infected patients: patients admitted to the hospital during the study period who are within the same risk set as the infected patients.
For all patients data collection will be performed by review of medical files, which will cover the entire admission during which they were included in the study, and all cause 30 day mortality. Data collection for the hospital stay covers confounders and effect modifiers of the associations studied, and feeds into the outcomes costs, DALYs and length of stay. For the cohort with gram-negative infections, data on infection parameters and antibiotic treatment parameters are also collected.
In addition, the subcohort with infections by multi-drug resistant organisms and a random 20% of the subcohort with infections by sensitive organisms will be selected for follow-up, consisting of sending questionnaires and renewed medical file review 30 days after the index culture date. In the case of ongoing sequelae of the gram-negative infection, this procedure is repeated 90 days after the index culture date. These questionnaires will feed into the outcomes costs, DALYs and quality-adjusted life years (QALYs).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Amersfoort, Netherlands
- Meander Medisch Centrum
-
Breda, Netherlands
- Amphia Ziekenhuis
-
Eindhoven, Netherlands
- Catharina Ziekenhuis
-
Hilversum, Netherlands
- Tergooi
-
Nieuwegein, Netherlands
- St. Antonius Ziekenhuis
-
Tilburg, Netherlands
- St. Elisabeth Ziekenhuis
-
Utrecht, Netherlands
- UMC Utrecht
-
Utrecht, Netherlands
- Diakonessenhuis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Please refer to descriptions of two cohorts
Exclusion Criteria:
- Patients on children's wards
- Patients admitted to wards for long-term care or psychiatric wards, that were not subsequently admitted to acute care wards as a consequence of the infection
- Patients admitted to wards that are excluded for logistic reasons such as the non-availability of electronic patient files, that were not subsequently admitted to included acute care wards as a consequence of the infection
- Patients that have been included in the cohort of infected patients during the same hospitalization or within the past 30 (if not eligible for follow-up) or 90 (if eligible for follow-up) days
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients with gram-negative infections
Sample (5/week/hospital) of all patients in a hospital that meet all of the following:
Date of entry into cohort: date of index culture of infection episode |
Non-infected patients
Matched sample of all patients that (1) were admitted to the hospital and (2) did not have a gram-negative infection according to the 4 criteria set out in the other group on the date used for matching. Selected by matching 1:1 to patients with gram-negative infections on (1) hospital, (2) length of hospital stay on the date the index culture for the infected patient was obtained, and (3) age. Date of cohort entry: date of index culture of matched infected patient |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality
Time Frame: Up to 30 days
|
Death (whether in-hospital or after discharge) from any cause, as apparent from medical record or municipal registry.
|
Up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Costs
Time Frame: Hospital stay (all patients; expected average 1 week) and up to 90 days (follow-up patients)
|
Costs generated from societal perspective, including:
Questionnaires are not available for the non-infected cohort, and therefore the costs for acquiring gram-negative infections can only be calculated from the hospital perspective. |
Hospital stay (all patients; expected average 1 week) and up to 90 days (follow-up patients)
|
DALYs
Time Frame: Up to 90 days
|
Years of Life Lost (YLL) and Years Lived with Disability (YLD) attributable to infection as apparent from an outcome tree of health outcomes related to gram-negative infections. This tree is preconceived, but modifiable according to observed sequelae in the study. A mathematical model for this outcome will be constructed that incorporates, apart from the observed sequelae in the study, factors such as (1) preexisting decreased life expectancy and quality of life due to comorbidity, (2) known transition parameters between health outcomes from literature, (3) confounding effects of comorbidity on transition parameters, (4) sequelae not observed within the time frame of data collection for the study, (5) 'baseline' change in health outcomes during hospitalization as apparent from the non-infected cohort, and (6) occupancy of several health outcome simultaneously. This outcome will not be calculated for the non-infected cohort. |
Up to 90 days
|
Length of stay
Time Frame: Hospital stay (expected average 1 week)
|
Number of days until hospital discharge.
|
Hospital stay (expected average 1 week)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QALYs
Time Frame: Up to 90 days
|
Measured by EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) in questionnaires, as a confirmation of the DALY model results. This outcome will not be calculated for the non-infected cohort. |
Up to 90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marc JM Bonten, MD PhD, UMC Utrecht, Utrecht, the Netherlands
- Study Chair: Heidi SM Ammerlaan, MD PhD, Catharina Hospital, Eindhoven, the Netherlands
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GRAND-ABC
- 205200007 (Other Grant/Funding Number: ZonMw)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection Resistant to Drugs
-
Seattle Children's HospitalRecruitingInfection Resistant to DrugsUnited States
-
Catholic University of the Sacred HeartUniversity Hospital, Geneva; Universiteit Antwerpen; Clinical Centre of Serbia; Canisius-Wilhelmina Hospital and other collaboratorsUnknownInfection Due to ESBL Bacteria | Bacterial Resistance | Infection Resistant to Multiple Drugs | Staph Aureus Methicillin Resistant ColonizationItaly, Romania, Serbia
-
Hat Yai Medical Education CenterTerminatedPneumonia, Ventilator-Associated | Colistin Adverse Reaction | Infection Due to Multidrug Resistant Acinetobacter | Infection Resistant to Multiple DrugsThailand
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacterial Infections | Infections Resistant to Multiple DrugsChina, United States, Australia, Colombia
-
The University of The West IndiesRecruiting
-
Northwell HealthWithdrawnPlatelet Dysfunction Due to Drugs
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
University of MiamiWithdrawnInfection Due to Resistant Organism
-
Istanbul Bakirkoy Maternity and Children Diseases...CompletedAdverse Reaction to Other Drugs and MedicinesTurkey